Ipsen
The Vice President, Biologics Process Development leads the Biologics Process Development organization at Ipsen, overseeing the CMC drug substance process development for novel biologics from candidate selection through commercialization. This role involves managing cross-functional teams, driving strategic CMC programs, and ensuring successful regulatory approvals and technology transfers. The position requires strong leadership, global stakeholder engagement, and expertise in biologics development within a pharmaceutical environment.
Headquarters
Paris, Île-De-France, France
Company Size
5001-10000 employees
Founded
1929
Ipsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Ipsen.
Ipsen didn’t post a salary, so this is our estimate from similar listings.
IPSEN (OTCMKTS:IPSEY) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened
9 hours ago
Director, Process Chemistry
IDEAYA Biosciences, Inc.
Vice President, CMC Drug & Device Development
kaileratherapeutics
Director, CMC Product Development – Biologics
Beeline Medicines
Vice President, Drug Substance
BioCryst Pharmaceuticals
Manager, Biologics Drug Substance External Manufacturing
Celldex Therapeutics
Associate Director, Drug Substance Manufacturing
Akero Therapeutics